PreImplantation Factor (PIF) orchestrates systemic antiinflammatory response by immune cells: effect on peripheral blood mononuclear cells - 27/09/12
, David Kirk, PhD b, Sivakumar Ramu, PhD c, Benjamin Rivnay, PhD d, Roumen Roussev, MD, PhD c, Michael J. Paidas, MD e
Reprints: Eytan R. Barnea, MD, 1697 Lark Lane, Cherry Hill, NJ 08003Résumé |
Objective |
Embryo-derived PreImplantation Factor (PIF) is essential for pregnancy immune modulation and synthetic PIF (sPIF), reverses neuroinflammation, and prevents diabetes mellitus through its immune modulatory properties. Herein, we explore sPIF's systemic effects on peripheral blood mononuclear cells (PBMCs).
Study Design |
sPIF's effects on PBMCs and subset populations from nonpregnant patients (n = 7) and male patients were evaluated by the assessment of binding characteristics, mixed lymphocyte reaction, proliferation, cytokine secretion, and associated gene expression. Data analysis was by analysis of variance (P < .05).
Results |
Fluorescein isothiocyanate–sPIF bound all myelomonocytic cells; binding was 30-fold up-regulated in mitogen-activated T and B cells (P < .05). sPIF decreased mixed lymphocyte reaction by 70% and blocked anti-CD3 antibody stimulated-PBMC proliferation by approximately 80% (P < .05). In naïve PBMCs, sPIF reduced interleukin (IL)-10 and -2; in activated PBMCs, sPIF increased IL-4, -5, -10, and -2, tumor necrosis factor–⍺, interferon-γ, and granulocyte-macrophage colony-stimulating factor (P < .05).
Conclusion |
Physiologic concentrations of PIF exert potent systemic antiinflammatory effects on nonpregnant activated immune cells.
Le texte complet de cet article est disponible en PDF.Key words : embryo, immune disorder, immune modulation, PreImplantation Factor
Plan
| Supported in part by a grant from the Consortium for Industrial Collaboration in Contraceptive Research of CONRAD (Arlington, VA), a Division of the Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, VA (E.R.B., principal investigator). |
|
| PreImplantation Factor (PIF) is a proprietary compound owned by BioIncept, LLC. E.R.B. is its (uncompensated) Chief Scientist; J. H. Barnea LLD, (uncompensated) President and CEO, is majority shareholder. Yale University received an unrestricted grant (M.J.P.). S.R. and R.R. received funding from BioIncept, LLC. D.K. and B.R. declare no conflict of interest. |
|
| Cite this article as: Barnea ER, Kirk D, Ramu S, et al. PreImplantation Factor (PIF) orchestrates systemic antiinflammatory response by immune cells: effect on peripheral blood mononuclear cells. Am J Obstet Gynecol 2012;207:313.e1-11. |
Vol 207 - N° 4
P. 313.e1-313.e11 - octobre 2012 Retour au numéro
Article précédent
- Nonstress testing at ≤32.0 weeks' gestation: a randomized trial comparing different assessment criteria
- Larry M. Cousins, Debra M. Poeltler, Sue Faron, Val Catanzarite, Sean Daneshmand, Holly Casele
- Single-nucleotide polymorphisms in genes involved in placental function and unexplained stillbirth
- Francesca Ferrari, Fabio Facchinetti, Huaizhi Yin, George R. Saade, Monica Longo
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?